Dermipsor Ltd. has reported detailed analysis of the results for the Phase 2b clinical trial of its product DPS-101. To be used in the treatment of psoriasis patients, DPS-101 is a new topical non-steroidal combination drug. It is a mix of two active ingredients - calcipotriol and nicotinamide. The multi-centre trial included 168 bilateral patients. Each side of the body of these patients was treated separately to evaluate the effectiveness of various doses of the medication. At the end of this 12 week study, half of the patients who received the highest dose of the drug achieved a condition of “clear to almost clear”. This is a significant improvement as compared to placebo.

Provectus Pharmaceuticals Inc has received allowance of its patent application in the European Union for its lead dermatology agent, PH-10, along with a number of related agents and their use. Provectus has also received allowance for another patent application in Canada, covering applicator devices used with PH-10 and related agents. PH-10 is currently undergoing phase 2 clinical testing in New York City for the treatment of moderate to severe psoriasis, and Provectus expects to commence phase 2 testing for another indication within the next few months.